Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.

Autor: Bodet-Milin C; Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France; caroline.milin@chu-nantes.fr., Faivre-Chauvet A; Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France., Carlier T; Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France., Ansquer C; Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France., Rauscher A; Pharmacy Unit, ICO Cancer Center, Saint-Herblain, France., Frampas E; Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France.; Pharmacy Unit, ICO Cancer Center, Saint-Herblain, France.; Radiology Department, University Hospital, Nantes, France., Toulgoat F; Radiology Department, University Hospital, Nantes, France., Masson D; Biology Department, University Hospital, Nantes, France., Bourgeois M; Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France., Cerato E; Délégation à la Recherche Clinique et à l'Innovation, University Hospital, Nantes, France., Rohmer V; Endocrinology Department, University Hospital, Angers, France., Couturier O; Nuclear Medicine Department, University Hospital, Angers, France., Drui D; Endocrinology Department, University Hospital, Nantes, France., Goldenberg DM; IBC Pharmaceuticals, Inc., Morris Plains, New Jersey., Sharkey RM; Immunomedics, Inc., Morris Plains, New Jersey; and., Barbet J; GIP Arronax, Saint-Herblain, France., Kraeber-Bodere F; Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Jazyk: angličtina
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Sep 01; Vol. 62 (9), pp. 1221-1227. Date of Electronic Publication: 2021 Feb 05.
DOI: 10.2967/jnumed.120.252791
Abstrakt: Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the 68 Ga-labeled IMP288 peptide for immuno-PET have been optimized in a first-in-humans study performed on medullary thyroid carcinoma (MTC) patients (the iPET-MTC study). The aim of this post hoc analysis was to determine the sensitivity of immuno-PET in relapsing MTC patients, in comparison with conventional imaging and 18 F-l-dihydroxyphenylalanine ( 18 F-DOPA) PET/CT. Methods: Twenty-five studies were analyzed in 22 patients. All patients underwent immuno-PET 1 and 2 h after 68 Ga-IMP288 injection pretargeted by TF2, in addition to neck, thoracic, abdominal, and pelvic CT; bone and liver MRI; and 18 F-DOPA PET/CT. The gold standard was histology or confirmation by one other imaging method or by imaging follow-up. Results: In total, 190 lesions were confirmed by the gold standard: 89 in lymph nodes, 14 in lungs, 46 in liver, 37 in bone, and 4 in other sites (subcutaneous tissue, heart, brain, and pancreas). The number of abnormal foci detected by immuno-PET was 210. Among these, 174 (83%) were confirmed as true-positive by the gold standard. Immuno-PET showed a higher overall sensitivity (92%) than 18 F-DOPA PET/CT (65%). Regarding metastatic sites, immuno-PET had a higher sensitivity than CT, 18 F-DOPA PET/CT, or MRI for lymph nodes (98% vs. 83% for CT and 70% for 18 F-DOPA PET/CT), liver (98% vs. 87% for CT, 65% for 18 F-DOPA PET/CT, and 89% for MRI), and bone (92% vs. 64% for 18 F-DOPA PET/CT and 86% for MRI), whereas sensitivity was lower for lung metastases (29% vs. 100% for CT and 14% for 18 F-DOPA PET/CT). Tumor SUV max at 60 min ranged from 1.2 to 59.0, with intra- and interpatient variability. Conclusion: This post hoc study demonstrates that anti-carcinoembryonic antigen immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than 18 F-DOPA PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination.
(© 2021 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze: MEDLINE
Externí odkaz: